Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

Leukemia

Volumn 26, Issue 2, 2012, Pages 199-213

  Van De Donk, N W C J ^a   Kamps, S ^a   Mutis, T ^a   Lokhorst, H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

bone marrow micro environment; immunomodulatory drugs; immunotherapy; monoclonal antibody; multiple myeloma; proteasome inhibitor

Indexed keywords

1 7 F 9; AVE 1642; BEVACIZUMAB; BHQ 880; BI 505; BORTEZOMIB; BT 062; CELL SURFACE PROTEIN; CS1 PROTEIN; CT 011; DACETUZUMAB; DARATUMUMAB; DENOSUMAB; DEXAMETHASONE; ELOTUZUMAB; FIGITUMUMAB; IMMU 110; IMMUNOMODULATING AGENT; IPH 2101; LENALIDOMIDE; LORVOTUZUMAB MERTANSINE; LUCATUMUMAB; MAPATUMUMAB; MILATUZUMAB; MONOCLONAL ANTIBODY; SAMALIZUMAB; SAR 650984; SILTUXIMAB; SYNDECAN 1; TABALUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE DISEASE; BONE MARROW; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ACTIVATION; CELL ADHESION; CELL DEATH; CYTOLYSIS; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFUSION RELATED REACTION; KIDNEY FAILURE; MAXIMUM TOLERATED DOSE; MICROENVIRONMENT; MONOTHERAPY; MULTIPLE MYELOMA; NATURAL KILLER CELL; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEINURIA; REVIEW; STROMA CELL; THROMBOCYTOPENIA; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL ADHESION; HUMANS; MULTIPLE MYELOMA;

EID: 84856701723     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.214     Document Type: Review

References (163)

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
2. Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002; 25: 72-81. (Pubitemid 34052837)
3. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002; 110: 71-79. (Pubitemid 34743467)
4. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24: 22-32.
5. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005; 128: 192-203.
6. van de Donk NW, Lokhorst HM, Bloem AC. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 2005; 19: 2177-2185. (Pubitemid 41741612)
7. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008; 112: 1329-1337.
8. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008; 14: 2775-2784.
9. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 2009; 8: 2616-2624.
10. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Leleu X et al. Elotuzumab in Combination with Lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma: interim results of a phase 1 study. ASH Annu Meet Abstr 2010; 116: 1936.
11. Richardson PG, Moreau P, Jakubowiak AJ, Facon T, Jagannath S, Vij R et al. Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. ASH Annual Meeting Abstracts 2010; 116: 986.
12. Jakubowiak AJ, Benson Jr DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A et al. Elotuzumab in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study. ASH Annual Meeting Abstracts 2010; 116: 3023.
13. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996; 94: 318-323. (Pubitemid 26247990)
14. Lutz RJ, Whiteman KR. Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 2009; 1: 548-551.
15. Tassone P, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004; 104: 3688-3696. (Pubitemid 39564446)
16. Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 1998; 91: 2679-2688. (Pubitemid 28227516)
17. Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y et al. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009; 15: 4028-4037.
18. Jagannath S, Chanan-Khan AA, Heffner LT, Avigan D, Lutz RJ, Uherek C et al. BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in a Phase I Study in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. ASH Annual Meeting Abstracts 2010; 116: 3060.
19. Zuber C, Daelken B, Aigner S, Haeder T, Ab O, Whiteman K et al. BT062, A CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy in Combination with Lenalidomide or Bortezomib. ASH Annual Meeting Abstracts 2010; 116: 3008.
20. Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993; 81: 2658-2663. (Pubitemid 23147570)
21. Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 2002; 117: 882-885. (Pubitemid 34639251)
22. Tassone P, Gozzini A, Goldmacher V, Shammas MA,Whiteman KR, Carrasco DR et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N20-deacetyl-N20-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 2004; 64: 4629-4636. (Pubitemid 38856937)
23. Whiteman K, Ab O, Bartle L, Foley K, Goldmacher V, Lutz R. Efficacy of IMGN901 (huN901-DM1) in combination with bortezomib and lenalidomide against multiple myeloma cells in preclinical studies. AACR Meeting Abstracts 2008; 2008: 2146.
24. Chanan-Khan A, Wolf JL, Garcia J, Gharibo M, Jagannath S, Manfredi D et al. Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple MyelomaFA Preliminary Efficacy Analysis. ASH Annual Meeting Abstracts 2010; 116: 1962.
25. Chanan-Khan A, Wolf J, Gharibo M, Jagannath S, Munshi NC, Anderson KC et al. Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple MyelomaFA Preliminary Safety and Efficacy Analysis. ASH Annual Meeting Abstracts 2009; 114: 2883.
26. Berdeja JG, Ailawadhi S, Niesvizky R, Wolf JL, Zildjian SH, O'Leary J et al. Phase I Study of Lorvotuzumab Mertansine (IMGN901) in Combination with Lenalidomide and Dexamethasone in Patients with CD56-Positive Relapsed or Relapsed/ Refractory Mulitple MyelomaFA Preliminary Safety and Efficacy Analysis of the Combination. ASH Annual Meeting Abstracts 2010; 116: 1934.
27. Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 2001; 25: 1-12. (Pubitemid 32012975)
28. de Weers M, Tai YT, van der Veer M, Bakker JM, Vink T, Jacobs DC et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-1848.
29. Tai YT, de Weers M, Li XF, Song W, Nahar S, Bakker JM et al. Daratumumab, A Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication. ASH Annual Meeting Abstracts 2009; 114: 608.
30. Groen RW, van der Veer M, Hofhuis FM, van Kessel B, de Weers M, Parren PWHI et al. In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab in the Treatment of Multiple Myeloma. ASH Annual Meeting Abstracts 2010; 116: 3058.
31. van der Veer M, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011; 96: 284-290.
32. Kong SY, Li XF, Nahar S, Song W, de Weers M, Parren PWHI et al. Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs. ASH Annual Meeting Abstracts 2010; 116: 3013.
33. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PWHI et al. Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab with Lenalidomide and Bortezomib. ASH Annual Meeting Abstracts 2010; 116: 3030.
34. Park PU, Blanc V, Deckert J, Lejeune P, Bartle LM, Skaletskaya A et al. SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies. ASH Annual Meeting Abstracts 2008; 112: 2756.
35. Lejeune P, Deckert J, Mayo M, Whiteman K, Johnson S, Guyre C et al. Abstract #859: broad spectrum of antitumor activity of SAR650984, a humanized anti-CD38 antibody targeting hematological malignancies. AACR Meeting Abstracts 2009; 2009: 859.
36. Lejeune P, Blanc V, Courta J, Egile C, Vrignaud P, Deckert J et al. Abstract #2797: in vivo therapeutic synergy of SAR650984, a humanized anti-CD38 antibody, in combination with melphalan in a multiple myeloma xenograft. AACR Meeting Abstracts 2009; 2009: 2797.
37. Schmidmaier R, Morsdorf K, Baumann P, Emmerich B, Meinhardt G. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int J Biol Markers 2006; 21: 218-222. (Pubitemid 46165212)
38. Veitonmaki N, Frendeus B, Danielsson L, Ljungars A. Apoptosisinducing ICAM-1 antibody BI-505 is a potent inhibitor of multiple myeloma. Clin Lymphoma Myeloma Leuk 2009; 9 (Suppl 1): S157 (abstract B599).
39. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84: 3063-3070. (Pubitemid 24328099)
40. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685-691.
41. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198-1204.
42. Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 2006; 107: 397-403. (Pubitemid 43053569)
43. Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007; 13: 6469-6478. (Pubitemid 350075037)
44. van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der LJ et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 1998; 102: 783-790. (Pubitemid 28387063)
45. Kurzrock R, Fayad L, Voorhees P, Furman RR, Lonial S, Borghaei H et al. A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease. ASH Annual Meeting Abstracts 2008; 112: 1009.
46. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374-14379. (Pubitemid 35257679)
47. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99: 1885-1893. (Pubitemid 34525465)
48. Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA et al. Targeted inhibition of interleukin sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009; 145: 481-490.
49. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011; 152: 579-592.
50. Rossi JF, Manges RF, Sutherland HJ, Jagannath S, Voorhees P, Sonneveld P et al. Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma. ASH Annual Meeting Abstracts 2008; 112: 867.
51. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498. (Pubitemid 41007864)
52. Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z et al. A high-affinity fully human anti-IL-6mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009; 15: 7144-7152.
53. Hirata T, Shimazaki C, Sumikuma T, Ashihara E, Goto H, Inaba T et al. Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro. Leuk Res 2003; 27: 343-349. (Pubitemid 36071392)
54. Tsunenari T, Koishihara Y, Nakamura A, Moriya M, Ohkawa H, Goto H et al. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood 1997; 90: 2437-2444. (Pubitemid 27392728)
55. Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT, Nishimoto N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res 2007; 67: 871-875.
56. Sakai A, Oda M, Itagaki M, Yoshida N, Arihiro K, Kimura A. Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical. Int J Hematol 2010; 92: 598-608.
57. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230. (Pubitemid 38402114)
58. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy Jr JD, Barlogie B et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009; 113: 4614-4626.
59. Descamps G, Wuilleme-Toumi S, Trichet V, Venot C, Debussche L, Hercend T et al. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol 2006; 177: 4218-4223. (Pubitemid 44359958)
60. Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, Amiot M. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 2009; 100: 366-369.
61. Moreau P, Hulin C, Facon T, Boccadoro M, Mery-Mignard D, Deslandes A et al. Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma. ASH Annual Meeting Abstracts 2007; 110: 1166.
62. Moreau P, Cavallo F, Leleu X, Hulin C, Amiot M, Descamps G et al. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia 2011; 25: 872-874.
63. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005; 11: 2063-2073. (Pubitemid 40471873)
64. Lacy MQ, AlsinaM, Fonseca R, Paccagnella ML, Melvin CL, Yin D et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26: 3196-3203.
65. Wu KD, Zhou L, Burtrum D, Ludwig DL, Moore MA. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 2007; 56: 343-357. (Pubitemid 46035904)
66. Jakob C, Wernecke T, Sterz J, Goerke A, Heider U, Kaiser M et al. An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma. ASH Annual Meeting Abstracts 2009; 114: 2802.
67. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428-435.
68. Koldehoff M, Beelen DW, Elmaagacli AH. Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma. J Leukoc Biol 2008; 84: 561-576.
69. Ria R, Vacca A, Russo F, Cirulli T, Massaia M, Tosi P et al. A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 2004; 92: 1438-1445. (Pubitemid 39642557)
70. Callander NS, Markovina S, Juckett MB, Wagner E, Kolesar J, Longo W et al. The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317). ASH Annual Meeting Abstracts 2009; 114: 3885.
71. Weber DM, Chen C, Niesvizky R,Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142. (Pubitemid 350146108)
72. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132. (Pubitemid 350146107)
73. Somlo G, Lashkari A, Bellamy W, Zimmerman T, Tuscano J, O'Donnell M et al. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol 2011; 154: 533-535.
74. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106: 1021-1030. (Pubitemid 41076449)
75. Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007; 13: 5903-5909. (Pubitemid 47583918)
76. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148-3157. (Pubitemid 38451693)
77. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006; 66: 6675-6682. (Pubitemid 44085624)
78. Roche PA, Cresswell P. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 1990; 345: 615-618.
79. Roche PA, Teletski CL, Stang E, Bakke O, Long EO. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci USA 1993; 90: 8581-8585. (Pubitemid 23277713)
80. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003; 197: 1467-1476. (Pubitemid 36686708)
81. Lantner F, Starlets D, Gore Y, Flaishon L, Yamit-Hezi A, Dikstein R et al. CD74 induces TAp63 expression leading to B-cell survival. Blood 2007; 110: 4303-4311. (Pubitemid 351377795)
82. Starlets D, Gore Y, Binsky I, Haran M, Harpaz N, Shvidel L et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006; 107: 4807-4816. (Pubitemid 43882632)
83. Becker-Herman S, Arie G, Medvedovsky H, Kerem A, Shachar I. CD74 is a member of the regulated intramembrane proteolysisprocessed protein family. Mol Biol Cell 2005; 16: 5061-5069. (Pubitemid 41566819)
84. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004; 10: 6606-6611. (Pubitemid 39346557)
85. Stein R, Smith MR, Chen S, Zalath M, Goldenberg DM. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clin Cancer Res 2009; 15: 2808-2817.
86. Stein R, Qu Z, Cardillo TM, Chen S, Rosario A, Horak ID et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004; 104: 3705-3711. (Pubitemid 39564448)
87. Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005; 11: 5257-5264. (Pubitemid 41003714)
88. Chang CH, Sapra P, Vanama SS, Hansen HJ, Horak ID, Goldenberg DM. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005; 106: 4308-4314. (Pubitemid 41775941)
89. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M et al. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 2008; 6: 1356-1364.
90. Kaufman J, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H et al. First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma. ASH Annual Meeting Abstracts 2008; 112: 3697.
91. Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994; 84: 2597-2603. (Pubitemid 24317392)
92. Tai YT, Podar K, Gupta D, Lin B, Young G, Akiyama M et al. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 2002; 99: 1419-1427. (Pubitemid 34547100)
93. Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 2003; 101: 2762-2769. (Pubitemid 36857641)
94. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 1995; 85: 1903-1912.
95. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950-1961. (Pubitemid 33115003)
96. Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P et al. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cellmediated cytotoxicity against multiple myeloma cells. Br J Haematol 2003; 121: 592-596. (Pubitemid 36645380)
97. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 2004; 64: 2846-2852. (Pubitemid 38500624)
98. Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005; 65: 11712-11720. (Pubitemid 41821732)
99. Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010; 95: 845-848.
100. Agura E, Niesvizky R, Matous J, Munshi N, Hussein M, Parameswaran RV et al. Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study. ASH Annual Meeting Abstracts 2009; 114: 2870.
101. Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 2010; 116: 3004-3012.
102. Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005; 65: 5898-5906. (Pubitemid 40911196)
103. BensingerW, Jagannath S, Becker PS, Anderson KC, Stadtmauer EA, Aukerman L et al. A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma. ASH Annual Meeting Abstracts 2006; 108: 3575.
104. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001; 98: 795-804.
105. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999; 13: 1817-1824. (Pubitemid 29535266)
106. Menoret E, Gomez-Bougie P, Geffroy-Luseau A, Daniels S, Moreau P, Le GS et al. Mcl-1L cleavage is involved in TRAIL-R1-and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 2006; 108: 1346-1352. (Pubitemid 44232035)
107. Locklin RM, Croucher PI, Russell RG, Edwards CM. Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. Leukemia 2007; 21: 805-812. (Pubitemid 46444566)
108. Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006; 11: 1175-1193. (Pubitemid 44035966)
109. Ghoshal P, Chitta K, Vujcic S, Gaddy J, Miles KM, Stein L et al. Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma. ASH Annual Meeting Abstracts 2009; 114: 2832.
110. Belch A, Sharma A, Spencer A, Tarantolo S, Bahlis NJ, Doval D et al. A Multicenter Randomized Phase II Trial of Mapatumumab, A TRAIL-R1 Agonist Monoclonal Antibody, in Combination with Bortezomib in Patients with Relapsed/ Refractory Multiple Myeloma (MM). ASH Annual Meeting Abstracts 2010; 116: 5031.
111. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
112. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510. (Pubitemid 351560519)
113. Benson Jr DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116: 2286-2294.
114. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 2008; 105: 1285-1290. (Pubitemid 351397045)
115. Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother 2011; 60: 61-73.
116. Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin0s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004; 10: 2253-2264. (Pubitemid 38445682)
117. Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killermediated killing of tumor cells. Blood 2009; 114: 2667-2677.
118. Zhang S, Liang J, Chen L, Homsi Y, Wang X, Feng H et al. Abstract #3245: enhanced NK cell mediated cytotoxicity against multiple myeloma (MM) cells by the combination of anti-KIR (1-7F9) monoclonal antibody (mAb) and lenalidomide. AACR Meeting Abstracts 2009; 2009: 3245.
119. Benson D, Bakan C, Zhang S, Alghothani L, Liang J, Hofmeister C et al. IPH2101, A Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect. ASH Annual Meeting Abstracts 2009; 114: 3870.
120. Benson Jr DM, Bakan C, Padmanaban S, Abonour R, Suvannasankha A, Jagannath S et al. IPH2101, A Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data. ASH Annual Meeting Abstracts 2010; 116: 1966.
121. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002; 32: 634-643. (Pubitemid 34257540)
122. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110: 296-304. (Pubitemid 47026847)
123. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-12297.
124. Rosenblatt J, Glotzbecker B, Mills H, Keefe W, Wellenstein K, Vasir B et al. CT-011, Anti-PD-1 Antibody, Enhances Ex-Vivo T Cell Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma. ASH Annual Meeting Abstracts 2009; 114: 781.
125. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14: 3044-3051.
126. Olteanu H, Harrington AM, Hari P, Kroft SH. CD200 expression in plasma cell myeloma. Br J Haematol 2011; 153: 408-411.
127. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006; 108: 4194-4197. (Pubitemid 44913292)
128. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 2008; 180: 699-705.
129. Mahadevan D, Lanasa MC, Whelden M, Faas SJ, Ulery TL, Kukreja A et al. First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) in Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM). ASH Annual Meeting Abstracts 2010; 116: 2465.
130. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 2004; 64: 2016-2023. (Pubitemid 38339448)
131. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 2006; 91: 192-199.
132. Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood 2008; 112: 159-168.
133. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002; 116: 278-290. (Pubitemid 34156975)
134. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98: 3534-3540.
135. Vanderkerken K, De LE, Shipman C, Asosingh K, Willems A, Van CB et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003; 63: 287-289. (Pubitemid 36152481)
136. Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Vescio R et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol 2009; 84: 650-656.
137. Henry D, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
138. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy Jr JD. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 2008; 42: 669-680.
139. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-2494. (Pubitemid 38010074)
140. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA et al. Anti-DKK1mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114: 371-379.
141. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessyz JD, Evans HR et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009; 24: 425-436.
142. Padmanabhan S, Beck J, Kelly K, Munshi N, Dzik-Jurasz A, Gangolli E et al. A Phase I/II study of BHQ880, a novel osteoblast activating, anti-DKK1 human monoclonal antibody, in relapsed and refractory multiple myeloma (MM) patients treated with zoledronic acid (Zol) and anti-myeloma therapy (MM Tx). ASH Annual Meeting Abstracts 2009; 114: 750.
143. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003; 111: 1771-1782. (Pubitemid 38057757)
144. von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007s; 21: 2025-2034. (Pubitemid 47299978)
145. Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 2010; 107: 5124-5129.
146. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106: 3160-3165. (Pubitemid 41565914)
147. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96: 671-675. (Pubitemid 30463390)
148. Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003; 102: 311-319. (Pubitemid 36759670)
149. Kumar S, Blade J, Crowley J, Goldschmidt H, Hoering A, Jagannath S et al. Natural History of Multiple Myeloma Relapsing after Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study. ASH Annual Meeting Abstracts 2009; 114: 2878.
150. Hadari Y, Schlessinger J. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. J Clin Invest 2009; 119: 1077-1079.
151. Qing J, Du X, Chen Y, Chan P, Li H, Wu P et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009; 119: 1216-1229.
152. Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006; 107: 4039-4046. (Pubitemid 43726812)
153. Tai YT, Muchhal U, Li XF, Nahar S, Song W, Horton H et al. XmAb(R)5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma. ASH Annual Meeting Abstracts 2009; 114: 609.
154. Kong SY, Nahar S, Li XF, Song W, Hu Y, Muchhal U et al. Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by A Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation. ASH Annual Meeting Abstracts 2010; 116: 4064.
155. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M et al. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 2006; 10: 295-307. (Pubitemid 44512192)
156. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009; 28: 231-242.
157. Tripodo C, Florena AM, Macor P, Di BA, Porcasi R, Guarnotta C et al. P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma. Curr Cancer Drug Targets 2009; 9: 617-625.
158. Wong M, Asvadi P, Dunn R, Jones D, Campbell D, Spencer A. MDX-1097 Binds Specifically to Kappa Myeloma Cells and Anti-Tumour Activity is Mediated by Multiple Effector Cells. ASH Annual Meeting Abstracts 2009; 114: 1846.
159. Spencer A, Walker P, Asvadi P, Wong M, Campbell D, Reed K et al. A phase 1 study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. ASCO Annual Meeting Abstracts 2010; 28: 8143.
160. Polson AG, Zheng B, Elkins K, Lau J, Go MA, Scales SJ et al. FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma. ASH Annual Meeting Abstracts 2009; 114: 3836.
161. Prabhala RH, Fulciniti M, Pelluru D, Nanjappa P, Pai C, Lee S et al. Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma. ASH Annual Meeting Abstracts 2010; 116: 456.
162. Weidner KM, Scheuer W, Thomas M, Baehner M, Seeber S, Kettenberger H et al. Anti-Angiogenic Activity of a Tetravalent Bispecific Antibody (TAvi6) Targeting VEGF and Angiopoietin-2. ASH Annual Meeting Abstracts 2010; 116: 4304.
163. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758. (Pubitemid 34525533)